Sign In
Buy MESO
$14.17
-0.380 (-2.61%)
At Close: Jul 31, 2026
Working with Parent Project Muscular Dystrophy and the Duchenne Registry on patient identification and trial awareness efforts
Mesoblast Limited (MESO) Discusses Cellular Medicine Platforms and Innovations at R&D Day Transcript
01:56am, Thursday, 09'th Apr 2026
Mesoblast Limited (MESO) Discusses Cellular Medicine Platforms and Innovations at R&D Day Transcript
Why Mesoblast's Move Into DMD Warrants A Speculative Buy (Upgrade)
01:26pm, Wednesday, 08'th Apr 2026
Mesoblast (MESO) is upgraded to a speculative Buy as Ryoncil outperforms in pediatric SR-aGVHD and advances rapidly into a registrational DMD trial. Ryoncil's DMD opportunity is underappreciated, with
Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation
09:07am, Wednesday, 08'th Apr 2026
Mesoblast outlines commercial strategy to double net revenues as Ryoncil ® approaches US$100M net revenue milestone since launch last year
Partnering with Parent Project Muscular Dystrophy to ensure timely access to the trial for eligible patients ~15,000 children are living with DMD in the U.S. NEW YORK, April 07, 2026 (GLOBE NEWSWIRE)
Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter
09:03pm, Monday, 06'th Apr 2026
Strong growth in February/March following January seasonality Net revenue approaches US$100M since launch NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global
Mesoblast to Host R&D Day on April 8, 2026
07:19pm, Tuesday, 17'th Mar 2026
NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host its inaugural R&D Day on Wedn
Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast
07:21pm, Wednesday, 11'th Mar 2026
NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the appointment of Tere
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them
10:02am, Tuesday, 03'rd Mar 2026
/PRNewswire/ -- USANewsGroup.com News Commentary - The global cell therapy market is projected to surpass $8.2 billion in 2026, driven by a wave of clinical
Mesoblast (NASDAQ:MESO) Shares Gap Down – What’s Next?
03:47am, Sunday, 01'st Mar 2026
Mesoblast Limited (NASDAQ: MESO - Get Free Report)'s stock price gapped down before the market opened on Friday. The stock had previously closed at $16.92, but opened at $15.80. Mesoblast shares last
Mesoblast Limited (MESO) Q2 2026 Earnings Call Transcript
02:27am, Friday, 27'th Feb 2026
Mesoblast Limited (MESO) Q2 2026 Earnings Call Transcript
Ryoncil® Profits Underpinning Substantial Growth Pipeline
07:42pm, Thursday, 26'th Feb 2026
Financial Results and Operational Update for Half-Year Ended December 31, 2025 Financial Results and Operational Update for Half-Year Ended December 31, 2025
Mesoblast Financial Results and Corporate Update Webcast
07:00am, Friday, 20'th Feb 2026
NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operation
Mesoblast (NASDAQ:MESO) Stock Price Passes Below 50-Day Moving Average – Time to Sell?
02:01am, Tuesday, 17'th Feb 2026
Mesoblast Limited (NASDAQ: MESO - Get Free Report) shares passed below its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $18.19 and traded as low as $16.50.
Mesoblast Touts High Survival Rates For FDA-Approved Cell Therapy
08:11am, Thursday, 12'th Feb 2026
In a press release on Wednesday, it was noted that Ryoncil has shown high survival rates in patients with steroid-refractory acute graft versus host disease, emphasizing the need for earlier intervent
